What the FDA labels say about taking them together
Moxifloxacin and pimavanserin
Pimavanserin's FDA label of June 18, 2026 names moxifloxacin in its warnings and precautions section; moxifloxacin's label does not name pimavanserin itself but warns about its class (Atypical antipsychotics). The pimavanserin label: “The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain …”
Check it at the source: the moxifloxacin FDA label on DailyMed (effective March 17, 2026, Macleods Pharmaceuticals Limited); the pimavanserin FDA label on DailyMed (effective June 18, 2026, Acadia Pharmaceuticals Inc.).
What does the moxifloxacin label say about pimavanserin?
Moxifloxacin's label does not name pimavanserin itself; it warns about its class (Atypical antipsychotics):
Moxifloxacin label, warnings and precautionsKnown prolongation of the QT interval Ventricular arrhythmias including torsade de pointes because QT prolongation may lead to an increased risk for these conditions Ongoing proarrhythmic conditions, such as clinically significant bradycardia and acute myocardial ischemia, Uncorrected hypokalemia or hypomagnesemia Class IA (for example, quinidine, procainamide) or Class III (for example, amiodarone, sotalol) antiarrhythmic agents Other drugs that prolong the QT interval such as cisapride, erythromycin …
Moxifloxacin label, warnings and precautionsPharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed.
Source: FDA drug label (Moxifloxacin), Macleods Pharmaceuticals Limited, effective March 17, 2026 (SPL set 182ecd0f-714f-42f0-9b16-fb604cf15786), via openFDA; the full label on DailyMed
What does the pimavanserin label say about moxifloxacin?
Pimavanserin label, warnings and precautionsThe use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin, moxifloxacin) [see Drug Interactions (7.1) ].
Source: FDA drug label (NUPLAZID), Acadia Pharmaceuticals Inc., effective June 18, 2026 (SPL set 1e6bea44-57d6-4bac-9328-46e1ee59f83b), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Moxifloxacin | Pimavanserin | |
|---|---|---|
| Labeled for | Bacterial infections | n/a |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $1.60 per mL 0.5% eye drops | $170.50 per capsule 34 mg capsule |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once